Your browser doesn't support javascript.
loading
Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates.
Pascal, Kristen E; Dudgeon, Drew; Trefry, John C; Anantpadma, Manu; Sakurai, Yasuteru; Murin, Charles D; Turner, Hannah L; Fairhurst, Jeanette; Torres, Marcela; Rafique, Ashique; Yan, Ying; Badithe, Ashok; Yu, Kevin; Potocky, Terra; Bixler, Sandra L; Chance, Taylor B; Pratt, William D; Rossi, Franco D; Shamblin, Joshua D; Wollen, Suzanne E; Zelko, Justine M; Carrion, Ricardo; Worwa, Gabriella; Staples, Hilary M; Burakov, Darya; Babb, Robert; Chen, Gang; Martin, Joel; Huang, Tammy T; Erlandson, Karl; Willis, Melissa S; Armstrong, Kimberly; Dreier, Thomas M; Ward, Andrew B; Davey, Robert A; Pitt, Margaret L M; Lipsich, Leah; Mason, Peter; Olson, William; Stahl, Neil; Kyratsous, Christos A.
Affiliation
  • Pascal KE; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Dudgeon D; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Trefry JC; Virology Division, US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland.
  • Anantpadma M; Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio.
  • Sakurai Y; Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio.
  • Murin CD; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California.
  • Turner HL; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California.
  • Fairhurst J; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Torres M; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Rafique A; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Yan Y; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Badithe A; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Yu K; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Potocky T; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Bixler SL; Virology Division, US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland.
  • Chance TB; Pathology Division, US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland.
  • Pratt WD; Virology Division, US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland.
  • Rossi FD; Center for Aerobiological Sciences, US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland.
  • Shamblin JD; Virology Division, US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland.
  • Wollen SE; Virology Division, US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland.
  • Zelko JM; Virology Division, US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland.
  • Carrion R; Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio.
  • Worwa G; Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio.
  • Staples HM; Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio.
  • Burakov D; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Babb R; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Chen G; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Martin J; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Huang TT; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Erlandson K; Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, Washington, DC.
  • Willis MS; Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, Washington, DC.
  • Armstrong K; Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, Washington, DC.
  • Dreier TM; Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, Washington, DC.
  • Ward AB; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California.
  • Davey RA; Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio.
  • Pitt MLM; Office of the Commander, US Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland.
  • Lipsich L; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Mason P; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Olson W; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Stahl N; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Kyratsous CA; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
J Infect Dis ; 218(suppl_5): S612-S626, 2018 11 22.
Article in En | MEDLINE | ID: mdl-29860496
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemorrhagic Fever, Ebola / Antibodies, Neutralizing / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: J Infect Dis Year: 2018 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemorrhagic Fever, Ebola / Antibodies, Neutralizing / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: J Infect Dis Year: 2018 Document type: Article Country of publication: United States